URAT1 inhibition in hyperuricemia and gout: from transporter biology to clinical precision therapy. [PDF]
Front ImmunolLi G, Wang Y, Zhang Z.
europepmc +1 more source
Management and long-term serum urate control in gout: a population-based primary care cohort study. [PDF]
Br J Gen PractPou MA +6 more
europepmc +1 more source
Metformin repurposing in gout: enhancing febuxostat efficacy through anti-inflammatory and metabolic modulation: a randomized controlled double-blind study. [PDF]
InflammopharmacologyAbdel-Sadek DN +2 more
europepmc +1 more source
In Silico Molecular Docking Studies and Xanthine Oxidase Inhibitory Activity of <i>Abies kawakamii</i> Leaf Extract and Its Constituent. [PDF]
Pharmaceuticals (Basel)Huang CY +7 more
europepmc +1 more source
Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio-renal-metabolic risk modulation. [PDF]
Eur Heart J Cardiovasc PharmacotherBorghi C, Fogacci F, Cicero AFG.
europepmc +1 more source
Efficacy and safety of low-dose combination urate-lowering agent therapy versus standard-dose monotherapy in patients with hyperuricemia and/or gout: a systematic review and meta-analysis of randomized controlled trials. [PDF]
BMC NephrolSakaguchi T +14 more
europepmc +1 more source
Uric Acid and Chronic Kidney Disease. [PDF]
Kidney MedYadlapalli S, Nekkalapudi DK, Wish JB.
europepmc +1 more source
Design, Synthesis, and Anticancer Evaluation of Febuxostat-Based Triazolyl Derivatives. [PDF]
Arch Pharm (Weinheim)Lu Y +6 more
europepmc +1 more source
Green Sensitive Derivative Emission Spectrofluorimetry for the Estimation of Repaglinide and Febuxostat Simultaneously in Dosage Forms and Spiked Human Plasma. [PDF]
LuminescenceMarie AA, Roshdy A.
europepmc +1 more source
Treatment sequence patterns of urate-lowering therapy in Korean patients with gout: A common data model-based study. [PDF]
PLoS OneKim MJ +5 more
europepmc +1 more source